Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Apr;37(4):637–641. doi: 10.1128/aac.37.4.637

Pharmacokinetics of rufloxacin in patients with impaired renal function.

G Perry 1, T G Mant 1, P J Morrison 1, S Sacks 1, J Woodcook 1, R Wise 1, B P Imbimbo 1
PMCID: PMC187727  PMID: 8388194

Abstract

The pharmacokinetics of rufloxacin were investigated in normal subjects and in patients with various degrees of renal failure after the administration of a single oral 400-mg dose. Twenty-four subjects were classified by glomerular filtration rate (GFR) normalized for body surface area. Group 1 subjects had GFRs of > 80 ml/min, group 2 subjects had GFRs from 30 to 80 ml/min, group 3 subjects had GFRs from 8 to 29 ml/min, and group 4 subjects had GFRs of < 8 ml/min. The patients in group 4 were on continuous peritoneal dialysis or underwent hemodialysis 48 h after dosing. Plasma and urinary rufloxacin concentrations were determined by high-performance liquid chromatography. A two-compartment model was used to calculate rufloxacin pharmacokinetic parameters. Apparent total body clearance of the drug was linearly related to GFR (r = 0.696; P < 0.01). The elimination half-life increased proportionally with the severity of renal impairment, with values of 30 +/- 3, 36 +/- 5, and 44 +/- 3 h in groups 1, 2, and 3, respectively. In patients with moderate renal failure, dosage adjustment of rufloxacin is not needed. The rufloxacin dose interval should be prolonged to 48 h as the GFR falls below 30 ml/min/1.73 m2.

Full text

PDF
637

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boerema J. B., Bach D., Jol C., Pahlmann W. Penetration of rufloxacin into human prostatic tissue and fluid. J Antimicrob Chemother. 1991 Oct;28(4):547–554. doi: 10.1093/jac/28.4.547. [DOI] [PubMed] [Google Scholar]
  2. Cecchetti V., Fravolini A., Fringuelli R., Mascellani G., Pagella P., Palmioli M., Segre G., Terni P. Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. J Med Chem. 1987 Mar;30(3):465–473. doi: 10.1021/jm00386a005. [DOI] [PubMed] [Google Scholar]
  3. Chantler C., Garnett E. S., Parsons V., Veall N. Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci. 1969 Aug;37(1):169–180. [PubMed] [Google Scholar]
  4. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  5. Cogo R., Rimoldi R., Mattina R., Imbimbo B. P. Steady-state pharmacokinetics of rufloxacin in elderly patients with lower respiratory tract infections. Ther Drug Monit. 1992 Feb;14(1):36–41. doi: 10.1097/00007691-199202000-00006. [DOI] [PubMed] [Google Scholar]
  6. Dirksen M., Focht J., Boerema J. Rufloxacin once daily in acute exacerbations of chronic bronchitis. Infection. 1991 Jul-Aug;19(4):297–300. doi: 10.1007/BF01644971. [DOI] [PubMed] [Google Scholar]
  7. Imbimbo B. P., Broccali G., Cesana M., Crema F., Attardo-Parrinello G. Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers. Antimicrob Agents Chemother. 1991 Feb;35(2):390–393. doi: 10.1128/aac.35.2.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Imbimbo B. P., Imbimbo E., Daniotti S., Verotta D., Bassotti G. A new criterion for selection of pharmacokinetic multiexponential equations. J Pharm Sci. 1988 Sep;77(9):784–789. doi: 10.1002/jps.2600770914. [DOI] [PubMed] [Google Scholar]
  9. Kisicki J. C., Griess R. S., Ott C. L., Cohen G. M., McCormack R. J., Troetel W. M., Imbimbo B. P. Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers. Antimicrob Agents Chemother. 1992 Jun;36(6):1296–1301. doi: 10.1128/aac.36.6.1296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mattina R., Bonfiglio G., Cocuzza C. E., Gulisano G., Cesana M., Imbimbo B. P. Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses. Chemotherapy. 1991;37(6):389–397. doi: 10.1159/000238885. [DOI] [PubMed] [Google Scholar]
  11. Mattina R., Cocuzza C. E., Cesana M., Bonfiglio G. In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates. Chemotherapy. 1991;37(4):260–269. doi: 10.1159/000238865. [DOI] [PubMed] [Google Scholar]
  12. Neuman M. Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96–121. doi: 10.2165/00003088-198814020-00003. [DOI] [PubMed] [Google Scholar]
  13. Rimoldi R., Fioretti M., Albrici A., Imbimbo B. P. Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections. Infection. 1992 Mar-Apr;20(2):89–93. doi: 10.1007/BF01711071. [DOI] [PubMed] [Google Scholar]
  14. Segre G., Cerretani D., Cerri D., Moltoni L. A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics. Drugs Exp Clin Res. 1988;14(12):747–754. [PubMed] [Google Scholar]
  15. Wise R., Andrews J. M., Matthews R., Wolstenholme M. The in-vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother. 1992 Jun;29(6):649–660. doi: 10.1093/jac/29.6.649. [DOI] [PubMed] [Google Scholar]
  16. Wise R., Johnson J., O'Sullivan N., Andrews J. M., Imbimbo B. P. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent. J Antimicrob Chemother. 1991 Dec;28(6):905–909. doi: 10.1093/jac/28.6.905. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES